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Idiopathic pulmonary fibrosis (IPF) is a rare lung disease of unknown origin leading rapidly
to death. This paper addresses the issue of whether sputum induction is a suitable tool to
study respiratory tract inflammation and potential biomarkers in IPF compared to COPD, a
fibrosing airway wall disease.
Methods
In a cross-sectional analysis, 15 IPF patients, 32 COPD and 30 healthy subjects underwent
sputum induction. Total sputum cell counts and the amount of TGF- β, IGF-1, IGF-2,
IGFBP-1, IGFBP-2, IGFBP-3, IL-8, IL-13, MMP-7, MMP-9, YKL-40, TNF-α and KL-6 in spu-
tum supernatant were analysed. We also profiled gene expression of cells in the induced
sputum for TGF-β, MMP-7, YKL-40, IGFBP-2, IL-6, IL-8 and TNF-α.
Results
IPF patients, like COPD, had increased sputum absolute number of neutrophils, eosino-
phils, macrophages and epithelial cells compared to HS. IPF sputum supernatants had
increased concentrations of IGFBP-2, IL-8, TGF-β, MMP-7, MMP-9 and KL-6 (p<0.05,
p<0.0001, p<0.05, p<0.05, p<0.0001, p<0.05 respectively) when compared to healthy sub-
jects where COPD had higher IL-6 and TNF-α levels than IPF (p<0.05 and p<0.05 respec-
tively) and HS (p<0.0001 and p<0.001 respectively) and higher IL-8 and MMP-9 than HS
(p<0.0001 and p<0.001 respectively). Conversely to IL-6 and TNF-α, MMP-7 was increased
in IPF compared to COPD (p<0.05). The KL-6 and MMP-7 protein levels in sputum were
inversely correlated with total lung capacity (TLC, % of predicted) in IPF patients (r = -0.73
and r = -0.53 respectively). Sputum gene expression analysis identified a significant in-
crease for IGFBP-2, IL-6, IL-8 and MMP-7 in IPF compared to HS (p<0.05, p<0.01, p<0.05
and p<0.0001 respectively) and for IGFBP-2, YKL-40, IL-6, IL-8 and MMP-7 compared to
COPD (p<0.01, p<0.01, p<0.05, p<0.01 and p<0.0001 respectively). Furthermore, gene
expression of TGF-βwas increased in IPF compared to COPD (p<0.001) but not to HS.
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Conclusion
Our data show clear increase in expression and production of IGFBP-2, IL-8 and MMP-7 in
sputum from patients with IPF that may contribute to the disease.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a rare lung disease of unknown origin leading rapidly to
death [1]. The diagnostic approach is complex and requires a multidisciplinary discussion [1].
Although bronchoalveolar lavage (BAL) is an important tool for evaluating interstitial lung
diseases (ILDs), induced sputum, which has demonstrated clinical interest in airway diseases
[2], has been proposed as a less invasive alternative [2–4]. The research with sputum in ILDs
has mainly focused on the cellularity so far and there has been few studies that have investi-
gated the molecular inflammatory pathways in IPF using sputum analysis [5].
Many biomarkers have already been studied both in serum and BAL from ILDs and in par-
ticular in IPF where inflammation seems to take part of the disease [6] in addition to the remod-
elling process [7]. Among those we can identify surfactant protein A or SP-A, surfactant protein
D or SP-D which has recently be identified to be correlated with pulmonary function and mor-
tality in IPF [8], the Krebs von den Lungen 6 or KL-6, type A immunoglobulin or IgA, periostin
[9–13], insulin-like growth factor binding protein or IGFBP-2 [14] and a chitinase-3-like-1
human cartilage glycoprotein or YKL-40 [15–16] which were found to be increased in serum
from IPF patients. As for BAL, matrix metalloproteinase-7 (MMP-7) [17] and YKL-40 [15]
were the main markers found to be raised in IPF compared to healthy subjects.
The aim of our study was to evaluate the potential of measuring biomarkers of the fibrosing
process in sputum from patients with IPF. As comparators we have recruited a group of
COPD, recognized to be an airway disease featuring fibrosis of the airway wall at the periphery
of the lung [18].
Materials and methods
We analysed the induced sputum of patients with IPF (n = 15) in comparison to healthy sub-
jects (n = 30) and COPD (n = 32). The diagnosis of IPF was made according to the interna-
tional recommendations of the ATS [1] using the respiratory function, HRCT scan, BAL
(when available), as well as the clinical history of the patient. We excluded all other causes of
ILD (such as asbestosis, hypersensitivity pneumonitis, pneumopathy associated with connec-
tive tissue diseases or toxic pneumonitis). All cases were discussed in our multidisciplinary dis-
cussion team about interstitial lung diseases composed of: a pulmonologist, a specialist in
pulmonary rehabilitation, a rheumatologist, a radiologist, a pathologist, a specialist in occupa-
tional medicine. COPD were diagnosed according to the GOLD [19] and healthy subjects
were recruited by advertisement in ambulatory care waiting room of the hospital. They all
denied any chronic respiratory disease and had FEV1 and FVC values above 80% predicted.
The protocol was approved by the ethics committee of CHU Liège, and all subjects gave
written consent before their enrolment (Belgian number: B707201422832; ref: 2014/302).
Sputum induction and processing
After premedication with 400 micrograms inhaled salbutamol, sputum was induced by inhala-
tion of hypertonic (NaCl 5%) or isotonic (NaCl 0.9%) saline according to the FEV1 value
(> or< than 65% predicted). Saline was combined with additional salbutamol delivered by an
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39.
ultrasonic nebulizer (Ultra-Neb 2000; Devilbiss, Somerset, PA, USA) with an output set at 0.9
ml/min. Each subject inhaled the aerosol for three consecutive periods of 5 min for a total of
15 min. For safety reasons, FEV1 was monitored throughout the induction and it was stopped
if FEV1 fell by more than 20% from baseline. The whole sputum was collected in a plastic con-
tainer, weighed, and homogenized by adding three volumes of phosphate-buffered saline
(PBS), vortexed for 30 s, and centrifuged at 800g for 10 min at 4˚C. Supernatant was separated
from cell pellet and stored at − 80˚C. The cells were resuspended in a solution containing
5mM dithiothreitol without Ca++ and Mg++ and gently rocked for 20 min at room tempera-
ture. The cell suspension was then centrifuged again at 400g at 4˚C for 10 min. Squamous
cells, total cell counts and cell viability checked by trypan blue exclusion were performed with
a manual hemocytometer [20]. The differential leukocyte count was obtained using a cytospin
stained with Rapi Diff II (Atom Scientific, Manchester UK) on 500 non squamous cells.
Biomarkers measurements in the induced sputum
We analysed several biomarkers assumed to be critical growth factors or chemokines in the
induced sputum. The concentration of IL-6, IL-13, TNF-α, MMP-7, YKL-40 were assessed by
ELISA multiplex using Fluorokine1 Multianalyte Profiling Kits (R and D Systems, Minneap-
olis, MN, USA) according to the manufacturer’s instructions. The detection limit for this
assays were 7-25-7-39-61 pg/ml respectively The concentration of the other proteins were
measured separately by ELISA: TGF- β, MMP-9, IL-8, IGF-1, IGFBP-1, IGFBP-2 and IGFBP-3
(DuoSet kit, R and D systems); IGF-2 (Mediagnost, Reutlingen, Germany); KL-6 (Lumipulse
G KL-6 Fujirebio Europe). The detection limits for these kits were 7-25-25-32-30-125-130-
450pg/ml and 100 U/ml respectively.
Gene expression in the induced sputum
PCR was used to profile gene expression of cells in the induced sputum for TGF–β, MMP-7,
YKL-40, IGFBP-2, IL-6, IL-8 and TNF-α in a subgroup of patients (HS n = 14; COPD n = 15,
IPF n = 12). mRNA expression was measured in total sputum cells by Taqman reverse tran-
scription quantitative polymerase chain reaction (RT-qPCR). RNA extraction, and RT-qPCR
were performed according to description of da Silva et al [21]. The house keeping gene rRNA
18S was used as the reference gene and the fold change was calculated from the median of
healthy subject group. Sequences of primers and probes used are listed in Table 1. All Probes
were labeled with reporter and double-quencher dyes 506-carboxyfluorescein/ZEN/30 Iowa
Black FQ (506-FAM/ZEN/30IBFQ). Probes and primers were synthesized by IDT (Integrated
DNA Technologies, Inc., Coralville, IA).
Primers and probes for 18S rRNA, IL-6 and IL-8 were designed by Gielen and al. [22]. The
sequences are listed in Table 1. PrimeTime1 qPCR Assays provide by IDT (Integrated DNA
Technologies, Inc., Coralville, IA) were used for IGFBP-2, MMP-7, TNF-α, TGF-β1 and YKL-
40. We only analysed samples with more than 50% of viability with less than 30% squamous
cells. We chose a cut-off of 20 CT for the 18S and excluded samples in which more than 20 CT
was needed to pick up 18S.
Pulmonary function tests
Lung function tests were performed in our routine respiratory laboratory at CHU Liège.
All spirometric tests performed for this study were measured using the pneumotachograph
JaegerMasterlab system (Erich Jaeger GmbH, Wuzburg, Germany). The expiratory volume in
one second (FEV) and forced vital capacity (FVC) were measured in accordance with the rec-
ommendations of the European Respiratory Society (ERS)[23]. The results are expressed in ml
Sputum biomarkers in IPF
PLOS ONE | DOI:10.1371/journal.pone.0171344 February 8, 2017 3 / 12
and as percentage of predicted normal values. The Tiffeneau index or FEV / FVC is expressed
as percentage. The diffusion capacity of CO (DLCO) and the ratio DLCO / VA were measured
by the single breath testing technique (Sensor Medics 2400 He / CO Analyzer System, Biltho-
ven, Netherlands).
Statistical analysis
Demographic and functional data were expressed as mean ± standard deviation (SD). Induced
sputum cellularity was expressed as median (minimum-maximum) because of a not normal
distribution. When the data showed normal distribution, they were compared with a one-way
ANOVA, followed by Tukey-Kramer’s post-hoc testing. When the data did not show a normal
distribution, they were compared by Kruskall-Wallis followed by Mann-Whitney testing. Cor-
relations between variables were assessed using Spearman’s rank correlation test. A p<0.05
was considered as significant.
Results
Subject demographic and functional characteristics
The demographic, functional and treatment characteristics of the subjects are given in Table 2.
Both disease groups were slightly older than healthy subjects. As expected both IPF and COPD
Table 1. Sequence of primers and probes.
Gene name Accession number sequence
IGFBP-2 NM 000597.2 Forward TTC ACA CAC CAG CAC TCC
reverse ACC TCT ACT CCC TGC ACA T
Probe AGC ATG GCC TGT ACA ACC TCA AAC A
TGF-β NM 000660.6 Forward GTT CAG GTA CCG CTT CTC G
reverse CCG ACT ACT ACG CCA AGG A
Probe ACC CGC GTG CTA ATG GTG GAA
MMP-7 NM 002423.4 Forward GAA TGT CCC ATA CCC AAA GAA TG
reverse GAT GAG GAT GAA CGC TGG A
Probe CAT ACA GGA AGT TAA TCC CTA GAC TGC TAC CA
IL-6 NM 000600.4 Forward CCA GGA GCC CAG CTA TGA AC
reverse CCC AGG GAG AAG GCA ACT G
Probe CCT TCT CCA CAA GCG CCT TCG GT
IL-8 NM 000584.3 Forward CTG GCC GTG GCT CTC TTG
reverse CCT TGG CAA AAC TGC ACC TT
Probe CAG CCT TCC TGA TTT CTG CAG CTC TGT GT
YKL-40 NM 001276.2 Forward TCT GGG TGT TGG AGG CTA T
reverse GCT CAA CAC ACT CAA GAA CAG
Probe TGT CTG TCG GAG GAT GGA ACT TTG G
TNF-α NM 000594.3 Forward TCA GCT TGA GGG TTT GCT AC
reverse TGC ACT TTG GAG TGA TCG G
Probe AGA TGA TCT GAC TGC CTG GGC C
18s (rRNA) x03205.1 Forward CGC CGC TAG AGG TGA AAT TCT
reverse CAT TCT TGG CAA ATG CTT TCG
Probe ACC GGC GCA AGA CGG ACC AGA
Primers and probes for 18S rRNA, IL-6 and IL-8 were designed by Gielen and al (22).
PrimeTime® qPCR Assays provided by IDT (Integrated DNA Technologies, Inc., Coralville, IA) were used for IGFBP-2, MMP-7, TNF-α, TGF-β and YKL-40.
doi:10.1371/journal.pone.0171344.t001
Sputum biomarkers in IPF
PLOS ONE | DOI:10.1371/journal.pone.0171344 February 8, 2017 4 / 12
had reduced FEV1 and FVC compared to healthy subjects but only COPD had a reduced FE1/
FVC ratio. Total lung volume (TLC), residual lung volume (VR), lung diffusing capacity
(DLCO) and transfert coefficient (KCO) were sharply reduced in the IPF group.
Sputum cellularity
Induced sputum (IS) from IPF patients showed an increased cellular concentration in compar-
ison to healthy subjects (Table 3). There was a reduction in the proportion of macrophage and
lymphocyte in IPF in comparison to healthy subjects. When expressed in absolute values, neu-
trophils, macrophages, eosinophils and epithelial cells were all significantly increased in IPF
compared to healthy subjects (Table 3). There was no significant difference between IPF and
COPD.
Sputum supernatant biomarkers
Several biomarkers were measured in sputum supernatant (Table 4). There was a significant
increase of IGFBP-2, IL-8, TGF-β, MMP-7, MMP-9 and KL-6 (p<0.05, p<0.0001, p<0.05,
p<0.05, p<0.0001, p<0.05 respectively) in IPF patients compared to HS. COPD had higher IL-
6 and TNFα levels than IPF (p<0.05 and p<0.05 respectively) and HS (p<0.0001 and p<0.001
respectively) and higher IL-8 and MMP-9 than HS (p<0.0001 and p<0.001 respectively). Con-
versely to IL-6 and TNF-α, MMP-7 was increased in IPF compared to COPD (p<0.05).
Table 2. Subject characteristics.
Healthy subjects (n = 30) COPD (n = 32) IPF (n = 15)
Age, yrs 55(9) 63(9)*** 72(9)***˚
Gender (M/F) 11/19 24/8 12/3
Height, cm 169(8) 171(9) 170(12)
Weight, Kg 72(12) 71(17) 76(13)
BMI, Kg/m2 25(3) 24(4) 26(3)
Smokers (Never/ex/Current), n 13/8/9 1/17/14 2/10/3
pack-yr 9(13) 47(32)*** 33(24)**
FEV1%pred 111(11) 49(16) 69(15)
FVC %pred 114(15) 81(14) 69(16)
FEV1/FVC % 80(4) 48(10) 76(11)
TLC, %pred nd 115(19) 68(14)
RV, %pred nd 192(58) 65(49)˚˚˚
DLCO %pred nd 56(14) 36(16)˚
KCO %pred nd 76(20) 59(16)
ICS (yes/no) 0/30 12/20 3/12
OCS (yes/no) 0/30 2/30 2/13
Data are expressed as mean (SD).
* p < 0.05 compared to healthy subjects.
** p < 0.001 compared to healthy subjects.
*** p < 0.0001 compared to healthy subjects.
˚ p < 0.05 compared to COPD.
˚˚ p < 0.001 compared to COPD.
˚˚˚ p < 0.0001 compared to COPD.
FEV1: forced expiratory volume in one second; FVC: forced vital capacity; TLC: total lung capacity; RV:
residual volume; DLCO: diffusion capacity of CO in the lung; ICS: inhaled corticosteroid; OCS: oral
corticosteroid.
doi:10.1371/journal.pone.0171344.t002
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Table 3. Sputum cell counts.
Healthy subjects COPD IPF
Sputum weight g 3,7(0,8–22,4) 2,2(0,4–11,5)* 2,5(0,8–4,4)*
cell x106 /g 0,8(0,2–7,6) 2,9(0,4–55,9)*** 3,5(0,4–19,5)**
Squamous cells % 18(1–31) 10(0–38)* 7(0–29)*
Viability % 78(45,3–94,5) 70(24–100) 73(31–89)
Macrophage % 25(4,4–80,5) 9(0–77,5)** 16(0–41,2)*
x103 /g 203(0–6085,8) 333(0–2275)** 716(0–5891,6)**
Lymphocyte % 1,6(0–6,2) 1,5(0–6) 0,6(0–13,2)*
x103 /g 10 (0–388,6) 39(0–506) 14 (0–1887,6)
Neutrophil % 64(6,5–94,6) 66(11–100) 74(44,4–100)
x103 /g 423(0–5266,2) 1429(129–55900)** 2775(201,6–13912,5)***
Eosinophil % 0,2(0–5,8) 2(0–81)*** 0,5(0–21,4)
x103 /g 0,4(0–207) 58(0–8455)*** 17(0–4181,6)*
Epithelial cell % 2,9(0,5–25,3) 3.4(0–30.4) 1,8(0–16,4)
x103 /g 23(0–831,6) 94(0–594)* 86(0–469)*
Results are expressed as median (min-max).
* p < 0.05 compared to healthy subjects.
** p < 0.001 compared to healthy subjects.
*** p < 0.0001 compared to healthy subjects.
doi:10.1371/journal.pone.0171344.t003
Table 4. Sputum supernatant biomarkers.
Healthy subjects COPD IPF
IGF-1 (ng/ml) 0(0–0) 0(0–0) 0(0–17)
IGF-2 (ng/ml) 0(0–20) 0(0–39) 0(0–24)
IGFBP-1 (ng/ml) 0(0–0) 0(0–0) 0(0–1)
IGFBP-2 (ng/ml) 30(0–120) 49(0–257) 59(3–693)*
IGFBP-3 (ng/ml) 167(24–1060) 196(53–1349) 222(109–786)
IL-8 (pg/ml) 46(0–381) 170(0–3287)*** 276(46–3083)***
TGF-β (pg/ml) 0(0–38) 16(0–60) 32(0–88)*
IL-6 (pg/ml) 23(3–216) 60(20–3113)*** 29(8–459)˚
IL-13 (pg/ml) 0(0–453,2) 0(0–496,3) 0(0–1283,5)
TNF-α (pg/ml) 6,8(2–24,4) 14(2–489)** 10(2–88)˚
MMP-7 (ng/ml) 20(2–93) 17(3–195) 46(0.008–190)* ˚
MMP-9 (ng/ml) 70(10–471) 264(31–969)** 415(18–970)***
YKL-40 (ng/ml) 8(0.8–33) 16(0.6–224) 15(0.002–204)
KL-6 (U/ml) 23(4–292) 44(4–975) 140(16–448)*
Results are expressed as median (min-max).
* p < 0.05 compared to healthy subjects.
** p < 0.001 compared to healthy subjects.
*** p < 0.0001 compared to healthy subjects.
˚ p < 0.05 compared to COPD.
˚˚ p < 0.001 compared to COPD.
˚˚˚ p < 0.0001 compared to COPD.
doi:10.1371/journal.pone.0171344.t004
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Sputum cell gene expression
Gene expression analysis identified a significant increase for IGFBP-2, IL-6, IL-8 and MMP-7
in IPF compared to HS (p<0.05, p<0.01, p<0.05 and p<0.0001 respectively) and for IGFBP-
2, YKL-40, IL-6, IL-8 and MMP-7 compared to COPD (p<0.01, p<0.01, p<0.05, p<0.01 and
p<0.0001 respectively). (Fig 1)(Table 5). Furthermore, gene expression of TGF-β was also
increased in IPF compared to COPD (p<0.001).
Biomarkers and impaired lung function
In IPF, there was an inverse correlation between sputum supernatant protein levels of MMP-7
and KL-6 and % predicted TLC (r = -0.53, r = -0.73 respectively) (Fig 2). Diffusion lung capac-
ity was not significantly related to any of the biomarkers.
Fig 1. Protein and gene levels of IGFBP-2, IL-8 and MMP-7 in sputum of IPF patients. a) IGFBP-2 level in
supernatant showing a significant increase in IPF compared to HS. b) Sputum cell gene expression of IGFBP-
2 showing a significant increase in IPF patients compared to COPD and HS. c) IL-8 level in supernatant
showing a significant increase in COPD and IPF compared to HS. d) Sputum cell gene expression of IL-8
showing a significant increase in IPF compared to COPD and HS. e) MMP-7 level in supernatant showing a
significant increase in COPD and IPF compared to HS. f) Sputum cell gene expression of MMP-7 showing a
significant increase in IPF compared to COPD and HS.
doi:10.1371/journal.pone.0171344.g001
Table 5. Sputum cell gene expression.
COPD IPF HS vs IPF HS vs COPD COPD vs IPF
fold change fold change p value p value p value
IGFBP-2 0.91 13.70 0,0385 ns 0,0011
IL-6 4.67 24.88 0,0042 ns 0,0478
IL-8 2.78 15.53 0,0193 ns 0,0037
MMP-7 0.35 70.43 <0,0001 ns <0,0001
TGF-β 0.62 5.02 ns ns 0,0005
TNF-α 1.15 2.53 ns ns ns
YKL-40 0.5 5.65 ns ns 0,0011
Data are presented as fold change relative expression to healthy subjects group. COPD: chronic obstructive pulmonary disease (n = 15); IPF: idiopathic
pulmonary fibrosis (n = 12), HS: healthy subjects (n = 14).
doi:10.1371/journal.pone.0171344.t005
Sputum biomarkers in IPF
PLOS ONE | DOI:10.1371/journal.pone.0171344 February 8, 2017 7 / 12
Relationship between age, gender and biomarkers
Our groups were not fully matched with respect to age, sex and gender and smoking status.
Therefore we performed a specific analysis in the HS group in which we didn’t find any corre-
lation between biomarkers and age, gender and smoking status (data not shown).
Discussion
Here we report for the first time concomitant measurement of gene expression and protein
levels of growth factors and matrix metalloproteinases in sputum from patients with IPF. We
confirmed that TGF- β, IL-8, KL-6 and MMP-7, known to be biomarkers in IPF based on
serum and BAL analysis, are also significantly higher in induced sputum from IPF patients.
Furthermore IGFBP-2, recently identified as a new protein involved in IPF [14], was also sig-
nificantly increased in sputum from IPF both at the gene and the protein level.
Sputum cell count of patients with IPF revealed an intense inflammatory pattern with raised
total cell counts including granulocytes, macrophages and epithelial cells confirming previous
finding of Beeh et al. [24]. This increased number of cells had already been described in BAL
of IPF patients [25] but with a different proportion of cells, the granulocytic component being
more prominent in sputum than in BAL at the expense of the lymphocyte and the macrophage
fraction [2, 26]. Interestingly, in our study, IPF patients did not differ from COPD with respect
to sputum cell counts. This would indicate that it is difficult to identify the main localisation of
the pathological process (lung versus airways) based on the sole sputum cell count.
Fig 2. Correlation between MMP-7 and KL-6 and TLC (% pred) in IPF. a) Correlation between level of
MMP-7 (ELISA) in supernatant of IPF patients and total lung capacity (TLC)(%predicted). b) Correlation
between level of KL-6 (ELISA) in supernatant of IPF and TLC (%predicted).
doi:10.1371/journal.pone.0171344.g002
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TGF-β, widely known as a key actor of fibrosis and known to be elevated in BAL of IPF
patients [27], was increased in sputum supernatant of IPF compared to healthy subjects. More-
over gene expression of TGF-β was significantly raised in IPF compared to COPD, another
disease featuring remodelling, though in the latter it mainly affects the airway compartment.
Our study also confirmed the importance of MMP-7, a matrix metalloproteinase specifi-
cally found to be raised both at gene and protein level in sputum from IPF compared to COPD
and HS. While MMP-9 was increased in both IPF and COPD, it is remarkable that the raised
expression and protein amount of MMP-7 was limited to patients with IPF compared to HS.
Our results are in keeping with those of Zuo et al. who reported a greater MMP-7 gene expres-
sion in lung tissues of IPF patients [28] and with those of Huh et al. who reported an increased
level of MMP-7 in BAL of IPF [29]. Supporting the role of MMP-7 in disease progression [17,
30], we interestingly found a negative correlation between MMP-7 levels and TLC (%pred), a
physiological marker of pulmonary restriction. As our study is cross sectional it does not dem-
onstrate that sputum MMP-7 would associate with a loss of lung volume over time but this
would require a longitudinal study to confirm.
We found a significant and specific increase in KL-6 in sputum supernatant from IPF. As
with MMP-7 there was also a negative correlation between TLC (%pred) and sputum protein
level of KL-6. KL-6 is well known as a biomarker in pulmonary fibrosis [9, 31] and is present
on the surface membrane of alveolar epithelial cells (AEC-II) and bronchiolar epithelial cells.
Serum KL-6 has been previously described as predictive of acute exacerbation of IPF [9] but is
not recognized as a marker of disease severity by itself. The fact that sputum levels of KL-6
relates to the loss of lung volume in our study suggests that sputum may be a more appropriate
compartment than serum to evaluate the epithelial and alveolar damage occurring in IPF.
We have recently shown that serum IGFBP-2 was raised in IPF [14]. Here we extend our
finding by showing that this protein was also specifically raised in sputum. The augmentation
was seen both at the gene and the protein level making it very consistent. This is an original
finding as the protein had not been measured in the airway/lung compartment of patients suf-
fering from IPF before. Of interest is that gene expression of IGFBP-2 in IPF was not only
increased compared to healthy subjects but also compared to COPD. There is however a previ-
ous report of increased IGFBP-2 in BAL of children with diverse interstitial lung diseases [32].
Therefore we cannot claim that IGFBP-2, though being a useful biomarker and relevant to
pathophysiology [14], is specific of IPF.
Gene expression of IL-6 in IPF was increased compared to both healthy subjects and COPD
though the protein level remained comparable to that measured in healthy subjects. In IPF IL-
6 is pro-mitogenic for fibroblasts due to the sustained activation of MAP Kinases in contrast to
what is seen normal fibroblast [33]. In order to explain that, as opposed to gene expression,
protein level was not increased, we cannot rule out the possibility of a local consumption of IL-
6 that participates to the fibrosing process. Conversely the high protein level of IL-6 in sputum
supernatant from COPD contrasting with poor gene expression may be seen as a consequence
of plasma exudation into the airways and is in keeping with our previous observation that spu-
tum cells from COPD produced less IL-6 than those of HS [34]. Confirming previous studies
[26], IL-8 was significantly increased in IPF compared to healthy subjects both at gene and at
protein level while, as for IL-6, the increase in COPD was only seen at the protein level. IL-8 is
known to be a strong chemotactic agent for neutrophils [35, 36] and could explain the greater
number of neutrophils infiltrating the airways in IPF and COPD.
As aforementioned, one of the potential limitation of the study is the cross sectional design
that precludes any interpretation of the predictive values of these biomarkers in the follow-up
of the patients. A further limitation is that we were unable to assess the expression and the lev-
els of the growth factors in patients receiving anti-fibrotic therapy. Finally the lack of perfect
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matching between our groups regarding age, gender and tobacco may be seen as a potential
confounding factor. However we have to say that it is extremely difficult to recruit a large
number of healthy subjects above the age of 65 yrs. To address this issue of potential confound-
ing factors we have assessed the relationship between age, gender and tobacco smoking and
protein and gene expression of biomarkers in the group of healthy subjects and we did not
find any significant correlation.
Conclusion
Our data show clear increase in expression and production of several growth factors and
matrix metalloproteinases and chemokine in sputum from patients with IPF. Whether sputum
analysis may become a suitable and less invasive tool than BAL to predict and monitor evolu-
tion of the disease and the response to treatment should be investigated in prospective longitu-
dinal trials.
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